









Markets
/
Stocks
/
nasdaq-urgn
/

Urogen Pharma Ltd

URGN

View Detailed Chart

19.350USD

-0.050-0.26%

Market hours （ET）Quotes delayed by 15 min

817.18MMarket Cap

LossP/E TTM



Urogen Pharma Ltd

19.350

-0.050-0.26%

Overview Company Financials

Financials

Intraday

30m

Today

-0.26%

5 Days

+2.11%

1 Month

+42.49%

6 Months

+72.61%

Year to Date

+81.69%

1 Year

+23.41%

View Detailed Chart

Agency Rating

Analyst Rating

Based on 8 analysts

BUY

Current Rating

34.375

Target Price

77.19%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

552

Total

Median

Average

Company name

Ratings

Analysts

Urogen Pharma Ltd

URGN

CRISPR Therapeutics AG

CRSP

Intellia Therapeutics Inc

NTLA

Ionis Pharmaceuticals Inc

IONS

Exact Sciences Corp

EXAS

IQVIA Holdings Inc

IQV

...

111

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

15m

30m

15m

30m

D

Buy

Sell(1)

Neutral(1)

Buy(9)

Indicators

Sell(1)

Neutral(1)

Buy(3)

Indicators

Value

Direction

MACD(12,26,9)

0.305

Buy

RSI(14)

75.848

Buy

STOCH(KDJ)(9,3,3)

90.025

Overbought

ATR(14)

1.024

High Vlolatility

CCI(14)

71.463

Neutral

Williams %R

5.714

Overbought

TRIX(12,20)

1.960

Sell

StochRSI(14)

72.444

Buy

Moving Average

Sell(0)

Neutral(0)

Buy(6)

Indicators

Value

Direction

MA5

19.096

Buy

MA10

18.351

Buy

MA20

16.348

Buy

MA50

12.122

Buy

MA100

11.324

Buy

MA200

11.277

Buy

News

More news coming soon, stay tuned...

Financial Indicators

EPS

No Data

Total revenue

No Data

Company

UroGen Pharma Ltd. Is an Israel-based biopharmaceutical company. The Company is engaged in building solutions for cancers and urologic diseases. UroGen has developed RTGelTM reverse-thermal hydrogel, a proprietary sustained release, hydrogel-based platform technology that has the potential to improve therapeutic profiles of existing drugs. Its lead product candidates include MitoGel and VesiGel are formulated using its proprietary reverse thermally triggered hydrogel, or RTGel, technology. MiroGel ( UGN-101) is a sustained release formulation of the chemotherapy agent Mitomycin C for the treatment of low-grade upper tract urothelial carcinoma, an urothelial cancer in the upper tract. VesiGel (UGN-102) is a sustained release formulation of a high dose Mitomycin C for the treatment of low grade non-muscle invasive bladder cancer (LG-NMIBC).

Ticker SymbolURGN

CompanyUrogen Pharma Ltd

CEOMs. Elizabeth A. (Liz) Barrett

Websitehttps://www.urogen.com/